<Anchor>



The number of new corona cases in Korea is expected to increase from yesterday (4th). It is expected that the number will be around 4,000 as the weekend effect disappears. Although the number of patients with severe cases appears to be on the decline, the omicron mutation, which is the cause of the surge in patients in the United States and major European countries, is also a variable for us.



Correspondent Han Seong-hee.



<Reporter> This



is a hospital in Daedeok-gu, Daejeon.



It is the first hospital designated as a base hospital in the Chungcheong area, where there was a shortage of beds for severe COVID-19 patients until last month.



After these efforts, 6,392 new corona beds have been prepared nationwide for about two months since November of last year.



No one has been waiting for more than one day to be assigned a bed for a week. [Park Hyang/Central Accident

Resolving



Headquarters Head of Prevention and Prevention: The number of hospital beds has been continuously expanded, the medical system has recovered and is entering the stabilization phase.]



has decreased noticeably.



The number of critically ill patients on the same day decreased by 42 from the previous day to 973, but it is the first time since the 21st of last month that the number fell below 1,000.



The number of new confirmed cases decreased by 102 to 3,024, maintaining the level of 3,000 for three days in a row.



While the government has decided to only announce the number of new infections on a weekly basis regarding omicron mutations, news of infections continued in some regions.



In Seoul, 5 people were added, and in Jeollabuk-do, 9 people were added.



[Park Hyang/Central Accident Control Headquarters Head of Prevention and Prevention: As the speed of Omicron increases, the risk of unvaccinated people will also increase and the effect will appear sooner.] The



government plans to introduce the first dose in the middle of this month with regard to oral treatment .

He said that he was in the process of final negotiations with the pharmaceutical company.